Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Total Current Liabilities (2020 - 2025)

Oncology Institute's Total Current Liabilities history spans 6 years, with the latest figure at $71.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 35.9% year-over-year to $71.0 million; the TTM value through Dec 2025 reached $71.0 million, up 35.9%, while the annual FY2025 figure was $71.0 million, 35.9% up from the prior year.
  • Total Current Liabilities reached $71.0 million in Q4 2025 per TOI's latest filing, up from $65.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $71.0 million in Q4 2025 to a low of $171572.0 in Q1 2021.
  • Average Total Current Liabilities over 5 years is $36.9 million, with a median of $34.1 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 18271.88% in 2022, then dropped 7.26% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $29.8 million in 2021, then fell by 0.26% to $29.7 million in 2022, then grew by 17.05% to $34.8 million in 2023, then soared by 50.09% to $52.2 million in 2024, then skyrocketed by 35.9% to $71.0 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Total Current Liabilities are $71.0 million (Q4 2025), $65.6 million (Q3 2025), and $64.8 million (Q2 2025).